Analyzing the Safety Data of JAK Inhibitors

Opinion Video Author(s): Panelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA), highlighting potential adverse effects and how these impact clinical decision-making. Video content above is prompted by the following: Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. A Population Health Approach to Managing Heart Failure A Population Health Approach to Managing Heart Failure 259 Prospect Plains Rd, Bldg H, Monroe, NJ 08831 © 2025 MJH Life Sciences® and AJMC®. All rights reserved.